Search
Rivastigmine
go.drugbank.com/drugs/DB00989ApprovedInvestigationalRivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN ZEN 13.3MG/24HSutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … [A245154] Notably, none of these agents are approved for use in the treatment of CAD.
Autologous cultured chondrocytes
go.drugbank.com/drugs/DB10997ApprovedInvestigationalIt has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigationalArtemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
rdESAT-6
go.drugbank.com/drugs/DB21906ApprovedrdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]
Tranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalAn irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine). … It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … [A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineMoexipril
go.drugbank.com/drugs/DB00691ApprovedInvestigationalMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen...
Categories: Agents Acting on the Renin-Angiotensin SystemDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.
Stannous chloride
go.drugbank.com/drugs/DB11056ApprovedStannous chloride is used as a source of tin in radiopharmaceutical kits. … These complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label].